CBPO - China Biologic Products Holdings, Inc.
| Previous Close | 87.12 |
| Open | 86.88 |
| Bid | 80.77 x 300 |
| Ask | 89.00 x 1000 |
| Day's Range | 85.09 - 86.88 |
| 52 Week Range | 71.85 - 120.46 |
| Volume | 140,417 |
| Avg. Volume | 221,659 |
| Market Cap | 2.84B |
| Beta | 1.28 |
| PE Ratio (TTM) | 36.02 |
| EPS (TTM) | 2.38 |
| Earnings Date | Aug 2, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 104.24 |
- GlobeNewswire•8 days ago
Investor Expectations to Drive Momentum within Criteo S.A, Prima BioMed, CoStar Group, DBV Technologies S.A, Hollysys Automation Technologies, and China Biologic Products — Discovering Underlying Factors of Influence
NEW YORK, April 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Markit•last monthSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPO
- GlobeNewswire•last month
Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, March 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- PR Newswire•2 months ago
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2017
-- 4Q17 Total Sales Up 12.2% YoY and Non-GAAP Adjusted Net Income Down 6.8% YoY in RMB terms, or Total Sales Up 16.1% YoY to $90.1 Million and Net Income Down 226.8% YoY to a net loss of $24.6 Million ...
- PR Newswire•2 months ago
China Biologic Products to Report Fourth Quarter and Fiscal Year 2017 Financial Results
BEIJING , Feb. 23, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- PR Newswire•2 months ago
China Biologic to Build New Collection Station in Hainan Province
BEIJING, Feb. 14, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its wholly-owned subsidiary Guizhou Taibang Biological Products Co. Ltd. ("Guizhou Taibang") received approval from the Hainan Provincial Health and Family Planning Commission on February 13, 2018 to build a new plasma collection station in Hainan Province. The new plasma collection station will be located in Wenchang City, which covers a collection territory with a population of approximately 600,000.
- Simply Wall St.•2 months ago
Should You Expect China Biologic Products Holdings Inc (NASDAQ:CBPO) To Continue Delivering An ROE Of 20.70%?
China Biologic Products Holdings Inc (NASDAQ:CBPO) outperformed the Biotechnology industry on the basis of its ROE – producing a higher 20.70% relative to the peer average of 16.12% over theRead More...
Markit•3 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPO
- Simply Wall St.•3 months ago
Has China Biologic Products Holdings Inc (NASDAQ:CBPO) Improved Earnings Growth In Recent Times?
Investors with a long-term horizong may find it valuable to assess China Biologic Products Holdings Inc’s (NASDAQ:CBPO) earnings trend over time and against its industry benchmark as opposed to simplyRead More...
- PR Newswire•3 months ago
China Biologic to Attend the 36th Annual J.P. Morgan Healthcare Conference
BEIJING , Jan. 8, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical ...
- PR Newswire•3 months ago
China Biologic Announces Corporate Update
BEIJING, Jan. 8, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its new Shandong facility has completed the on-site GMP inspection and the inspection on the sample products by the China Food and Drug Administration ("CFDA"). The Company now awaits the CFDA's approval of the production license transfer for each product from the old facility to the new facility and expects to receive the new facility's final production certificate in late February, when full operations at the new facility will also begin.
Markit•4 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding CBPO totaled $184 million.
- PR Newswire•4 months ago
China Biologic Announces Completion of Acquisition of TianXinFu from PWM
BEIJING , Jan. 3, 2018 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ( "CBPO" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company ...
- Simply Wall St.•4 months ago
How Do Analysts See China Biologic Products Holdings Inc (NASDAQ:CBPO) Performing Over The Next Few Years?
In September 2017, China Biologic Products Holdings Inc (NASDAQ:CBPO) announced its latest earnings update, which confirmed that the company gained from a robust tailwind, leading to a double-digit earnings growthRead More...
- Capital Cube•4 months ago
China Biologic Products Holdings, Inc. breached its 50 day moving average in a Bearish Manner : CBPO-US : December 28, 2017
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for China Biologic Products Holdings, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)
- Simply Wall St.•4 months ago
Should You Be Tempted To Buy China Biologic Products Holdings Inc (NASDAQ:CBPO) Because Of Its PE Ratio?
China Biologic Products Holdings Inc (NASDAQ:CBPO) trades with a trailing P/E of 19.9x, which is lower than the industry average of 29.5x. While CBPO might seem like an attractive stockRead More...
- PR Newswire•4 months ago
China Biologic Receives Operating Permit for New Collection Facility in Ju County in Shandong Province
BEIJING, Dec. 15, 2017 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO)("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that, the Company's majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd. ("Shandong Taibang"), has recently received the operating permit from local authorities to commence plasma collection at its new branch collection facility in Ju County in Rizhao City, Shandong Province.
- Simply Wall St.•4 months ago
Has China Biologic Products Holdings Inc (CBPO) Got Enough Cash To Cover Its Short-Term Obligations?
Stocks with market capitalization between $2B and $10B, such as China Biologic Products Holdings Inc (NASDAQ:CBPO) with a size of $2.22B, do not attract as much attention from the investingRead More...
Markit•5 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, ETFs holding CBPO are favorable with net inflows of $7.22 billion.
- Simply Wall St.•5 months ago
What Do Analysts Think About China Biologic Products Holdings Inc’s (CBPO) Growth?
China Biologic Products Holdings Inc (NASDAQ:CBPO) is expected to deliver a solid 16.97% in earnings growth per share over the next year. At a current EPS of $4.002, this growthRead More...
Markit•5 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ETFs that hold CBPO had net inflows of $825 million over the last one-month.
Markit•5 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
China Biologic Products Holdings Inc NASDAQ/NGS:CBPO
Markit•5 months agoSee what the IHS Markit Score report has to say about China Biologic Products Holdings Inc.
Short interest is low for CBPO with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $527 million over the last one-month into ETFs that hold CBPO are among the lowest of the last year and appear to be slowing.
- Simply Wall St.•5 months ago
Calculating The Intrinsic Value Of China Biologic Products Holdings Inc (CBPO)
In this article I am going to calculate the intrinsic value of China Biologic Products Holdings Inc (NASDAQ:CBPO) using the discounted cash flows (DCF) model. Anyone interested in learning aRead More...
